Yang Li1,2, Xiaohong Su1, Wenjing Le1, Sai Li1, Zhaoyan Yang3, Christine Chaisson3, Guillermo Madico4, Xiangdong Gong1, George W Reed5,6, Baoxi Wang1,7, Peter A Rice5. 1. Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing. 2. Affiliated Qingdao Municipal Hospital of Qingdao University, China. 3. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health. 4. National Emerging Infectious Diseases Laboratories, Boston University. 5. Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester. 6. Corrona Research Foundation, Albany, New York. 7. Department of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
BACKGROUND: Mycoplasma genitalium (MG) causes symptomatic urethritis in men, and can infect alone or together with other sexually transmitted infection (STI) agents. METHODS: The prevalence of MG and other STIs was determined in 1816 men with symptomatic urethritis. Resistance of MG to macrolides and fluoroquinolones was determined by sequencing; the impact of recent antimicrobial usage on the distribution of MG single or mixed infections was determined. RESULTS: Overall, prevalence of MG infection was 19.7% (358/1816). Fifty-four percent (166/307) of MG infections occurred alone in the absence of other STI agents. Men with single MG infection self-administered or were prescribed antibiotics more often in the 30 days prior to enrollment than subjects with urethritis caused by MG coinfection (P < .0001). Higher rates (96.7%) of infection with macrolide resistance in MG were identified in men who had taken macrolides prior to enrollment (P < .03). Overall, 88.9% (303/341) of 23S ribosomal RNA (rRNA) genes contained mutations responsible for macrolide resistance; 89.5% (308/344) of parC and 12.4% (42/339) of gyrA genes had mutations responsible for fluoroquinolone resistance. Approximately 88% (270/308) of MG had combined mutations in 23S rRNA and parC genes; 10.4% (32/308) had mutations in all 3 genes. CONCLUSIONS: MG was the single pathogen identified in 11% of men with symptomatic urethritis. Overall, nearly 90% of MG infections were resistant to macrolides and fluoroquinolones. Men who took macrolides in the 30 days prior to enrollment had higher rates (97%) of macrolide-resistant MG. Resistance was associated with numerous mutations in 23SrRNA, parC, and gyrA genes.
BACKGROUND:Mycoplasma genitalium (MG) causes symptomatic urethritis in men, and can infect alone or together with other sexually transmitted infection (STI) agents. METHODS: The prevalence of MG and other STIs was determined in 1816 men with symptomatic urethritis. Resistance of MG to macrolides and fluoroquinolones was determined by sequencing; the impact of recent antimicrobial usage on the distribution of MG single or mixed infections was determined. RESULTS: Overall, prevalence of MG infection was 19.7% (358/1816). Fifty-four percent (166/307) of MG infections occurred alone in the absence of other STI agents. Men with single MG infection self-administered or were prescribed antibiotics more often in the 30 days prior to enrollment than subjects with urethritis caused by MG coinfection (P < .0001). Higher rates (96.7%) of infection with macrolide resistance in MG were identified in men who had taken macrolides prior to enrollment (P < .03). Overall, 88.9% (303/341) of 23S ribosomal RNA (rRNA) genes contained mutations responsible for macrolide resistance; 89.5% (308/344) of parC and 12.4% (42/339) of gyrA genes had mutations responsible for fluoroquinolone resistance. Approximately 88% (270/308) of MG had combined mutations in 23S rRNA and parC genes; 10.4% (32/308) had mutations in all 3 genes. CONCLUSIONS:MG was the single pathogen identified in 11% of men with symptomatic urethritis. Overall, nearly 90% of MG infections were resistant to macrolides and fluoroquinolones. Men who took macrolides in the 30 days prior to enrollment had higher rates (97%) of macrolide-resistant MG. Resistance was associated with numerous mutations in 23SrRNA, parC, and gyrA genes.
Authors: Andrew Lau; Catriona S Bradshaw; Dyani Lewis; Christopher K Fairley; Marcus Y Chen; Fabian Y S Kong; Jane S Hocking Journal: Clin Infect Dis Date: 2015-08-03 Impact factor: 9.079
Authors: Jamie Perin; Jenell S Coleman; Jocelyn Ronda; Erica Neibaur; Charlotte A Gaydos; Maria Trent Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830
Authors: Joyce F Braam; David J Hetem; Clarissa E Vergunst; Sophie Kuizenga Wessel; Martijn S van Rooijen; Roel H T Nijhuis; Maarten F Schim van der Loeff; Alje P van Dam; Sylvia M Bruisten Journal: PLoS One Date: 2020-10-20 Impact factor: 3.240
Authors: Lisa E Manhart; William M Geisler; Catriona S Bradshaw; Jørgen S Jensen; David H Martin Journal: Emerg Infect Dis Date: 2022-08 Impact factor: 16.126